Fischer Medical Ventures Ltd has informed the exchange the audited results as on 31.03.2025
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures Ltd reported audited results for FY25 with a clean, unmodified audit opinion from M/s Bilimoria Mehta & Co. On a standalone basis, revenue from operations dropped sharply to ₹521.97 lakhs (FY24: ₹1,152.83 lakhs), but profit after tax rose about 65% to ₹66.32 lakhs (FY24: ₹40.28 lakhs), supported by other income. On a consolidated basis, revenue jumped multi-fold to ₹11,069.87 lakhs (FY24: ₹2,098.13 lakhs), while consolidated PAT declined to ₹120.79 lakhs (FY24: ₹183.79 lakhs) due to share of losses from associates and higher costs. The company raised ~₹27,000 lakhs via fresh share issuance and premium, deployed heavily into subsidiaries and fixed deposits, and incorporated multiple new entities. The Board recommended a final dividend of ₹0.05 per share and recommended seeking listing on the NSE main board.
For shareholders, the standalone PBT more than doubled even as revenue shrank, suggesting better margins in the parent, while the massive consolidated revenue surge reflects aggressive expansion through new subsidiaries funded by fresh equity. The heavy investment outflows and negative standalone operating cash flow (₹-2,280.64 lakhs) signal a growth-investment phase, and the proposed NSE listing could improve liquidity and visibility for investors.